Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance

Drug Resistance Updates

Volumn 8, Issue 5, 2005, Pages 311-321

  Richardson, Alan ^a   Kaye, Stan B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Apoptosis; Carboplatin; Chemotherapy; Drug resistance; Ovarian cancer; Paclitaxel; Transcription factors

Indexed keywords

17 AAG; 5 AZA 2' DEOXYCYTIDINE; AEG 35156; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INDUCING FACTOR; AT 585; ATRASENTAN; AZD 0530; CANERTINIB; CANFOSFAMIDE; CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; CYTOKINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GX 015 070; IMATINIB; MLN 120; OBLIMERSEN; OSI 930; PHENOXODIOL; PI 103; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SPC 2996; TRAIL RECEPTOR ANTIBODY; TRANSCRIPTION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DNA DAMAGE; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; EXCISION REPAIR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; MISMATCH REPAIR; OVARY CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEADY STATE; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

EID: 27944481777     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2005.09.001     Document Type: Article

References (106)

1. M.R. Abedini, Q. Qiu, X. Yan, and B.K. Tsang Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro Oncogene 23 2004 6997 7004
2. S. Abuharbeid, J. Apel, G. Zugmaier, C. Knabbe, M. Sander, S. Gilbert, F. Czubayko, and A. Aigner Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells Naunyn Schmied. Arch. Pharmacol. 371 2005 141 151
3. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat. Cancer Rev. 3 2003 502 516
4. D.A. Altomare, H.Q. Wang, K.L. Skele, A. De Rienzo, A.J. Klein-Szanto, A.K. Godwin, and J.R. Testa Akt and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor growth Oncogene 23 2004 5853 5857
5. K. Aoki, T. Ogawa, Y. Ito, and S. Nakashima Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma Oncol. Rep. 11 2004 375 379
6. E. Asselin, G.B. Mills, and B.K. Tsang XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells Cancer Res. 61 2001 1862 1868
7. C. Balch, T.H. Huang, R. Brown, and K.P. Nephew The epigenetics of ovarian cancer drug resistance and resensitization Am. J. Obstet. Gynecol. 191 2004 1552 1572
8. A. Bellacosa, D. DeFeo, A.K. Godwin, D.W. Bell, J.Q. Cheng, and D.A. Altomare Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas Int. J. Cancer 64 1995 280 285
9. A. Berchuck, E.S. Iversen, J.M. Lancaster, J. Pittman, J. Luo, P. Lee, S. Murphy, H.K. Dressman, P.G. Febbo, M. West, J.R. Nevins, and J.R. Marks Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers Clin. Cancer Res. 11 2005 3686 3696
10. M. Bonovich, M. Olive, E. Reed, B. O'Connell, and C. Vinson Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines Cancer Gene Ther. 9 2002 62 70
11. V. Brabec, and J. Kasparkova Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs Drug Resist. Update 8 2005 131 146
12. A. Brozovic, G. Fritz, M. Christmann, J. Zisowsky, U. Jaehde, M. Osmak, and B. Kaina Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance Int. J. Cancer 112 2004 974 985
13. J.K. Chan, H. Pham, X.J. You, N.G. Cloven, R.A. Burger, G.S. Rose, K. Van Nostrand, M. Korc, P.J. Disaia, and H. Fan Suppression of ovarian cancer cell tumorigenicity and evasion of cisplatin resistance using a truncated epidermal growth factor receptor in a rat model Cancer Res. 65 2005 3243 3248
14. T. Chen, Y. Pengetnze, and C.C. Taylor Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3 Mol. Cancer Ther. 4 2005 217 224
15. Y.J. Chen, C.C. Yuan, K.C. Chow, P.H. Wang, C.R. Lai, M.S. Yen, and L.S. Wang Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients Gynecol. Oncol. 97 2005 110 117
16. J.Q. Cheng, X. Jiang, M. Fraser, M. Li, H.C. Dan, M. Sun, and B.K. Tsang Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase /Akt pathway Drug Resist. Update 5 2002 131 146
17. J. Cummings, T.H. Ward, E. LaCasse, C. Lefebvre, M. St-Jean, J. Durkin, M. Ranson, and C. Dive Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP Br. J. Cancer 92 2005 532 538
18. M. Cuello, S.A. Ettenberg, M.M. Nau, and S. Lipkowitz Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells Gynecol. Oncol. 81 2001 380 390
19. A.D. D'Andrea The Fanconi anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers Cell Cycle 2 2003 290 292
20. P.M. Das, and R. Singal DNA methylation and cancer J. Clin. Oncol. 22 2004 4632 4642
21. D. Del Bufalo, V. Di Castro, A. Biroccio, M. Varmi, D. Salani, L. Rosano, D. Trisciuoglio, F. Spinella, and A. Bagnato Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation Mol. Pharmacol. 61 2002 524 532
22. H.B. Deng, M. Adikari, H.K. Parekh, and H. Simpkins Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase Cancer Chemother. Pharmacol. 54 2004 301 307
23. H.B. Deng, H.K. Parekh, K.C. Chow, and H. Simpkins Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells J. Biol. Chem. 277 2002 15035 15043
24. M.R. Dewji Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn? J. Chemother. 16 Suppl. 4 2004 44 48
25. Z. Duan, K.A. Brakora, and M.V. Seiden Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells Mol. Cancer Ther. 3 2004 833 838
26. Z. Duan, Y. Duan, D.E. Lamendola, R.Z. Yusuf, R. Naeem, R.T. Penson, and M.V. Seiden Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin- resistant human cancer cell lines Clin. Cancer Res. 9 2003 2778 2785
27. Z. Duan, D.E. Lamendola, Y. Duan, R.Z. Yusuf, and M.V. Seiden Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines Cancer Chemother. Pharmacol. 55 2005 277 285
28. H. Dushkin, and R.J. Schilder Imatinib mesylate and its potential implications for gynecologic cancers Curr. Treat. Options Oncol. 6 2005 115 120
29. L.A. Emens Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer Am. J. Ther. 12 2005 243 253
30. B.N. Fahy, M.G. Schlieman, S. Virudachalam, and R.J. Bold Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer J. Am. Coll. Surg. 198 2004 591 599
31. M. Fraser, B.M. Leung, X. Yan, H.C. Dan, J.Q. Cheng, and B.K. Tsang p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells Cancer Res. 63 2003 7081 7088
32. L. Gatti, G.L. Beretta, N. Carenini, E. Corna, F. Zunino, and P. Perego Gene expression profiles in the cellular response to a multinuclear platinum complex Cell. Mol. Life Sci. 61 2004 973 981
33. G.V. Georgakis, Y. Li, R. Humphreys, M. Andreeff, S. O'Brien, M. Younes, A. Carbone, V. Albert, and A. Younes Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death Br. J. Haematol. 130 2005 501 510
34. G. Gifford, J. Paul, P.A. Vasey, S.B. Kaye, and R. Brown The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin. Cancer Res. 10 2004 4420 4426
35. S. Goto, K. Kamada, Y. Soh, Y. Ihara, and T. Kondo Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs Jpn. J. Cancer Res. 93 2002 1047 1056
36. R.S. Herbst, and S.R. Frankel Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer Clin. Cancer Res. 10 2004 4245s 4248s
37. R. Ho, A. Eggert, T. Hishiki, J.E. Minturn, N. Ikegaki, P. Foster, A.M. Camoratto, A.E. Evans, and G.M. Brodeur Resistance to chemotherapy mediated by TrkB in neuroblastomas Cancer Res. 62 2002 6462 6466
38. A.K. Holzer, G. Samimi, K. Katano, W. Naerdemann, X. Lin, R. Safaei, and S.B. Howell The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells Mol. Pharmacol. 66 2004 817 823
39. L. Hu, J. Hofmann, Y. Lu, G.B. Mills, and R.B. Jaffe Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Res. 62 2002 1087 1092
40. R. Jakobi Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis Drug Resist. Update 7 2004 11 17
41. A. Jimeno, and M. Carducci Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer Expert Rev. Anticancer Ther. 5 2005 419 427
42. K. Kamath, L. Wilson, F. Cabral, and M.A. Jordan {Beta}III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability J. Biol. Chem. 280 2005 12902 12907
43. M. Kamsteeg, T. Rutherford, E. Sapi, B. Hanczaruk, S. Shahabi, M. Flick, D. Brown, and G. Mor Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells Oncogene 22 2003 2611 2620
44. M. Karin, and A. Lin NF-kappaB at the crossroads of life and death Nat. Immunol. 3 2002 221 227
45. K. Katano, A. Kondo, R. Safaei, A. Holzer, G. Samimi, M. Mishima, Y.M. Kuo, M. Rochdi, and S.B. Howell Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper Cancer Res. 62 2002 6559 6565
46. K. Katano, R. Safaei, G. Samimi, A. Holzer, M. Rochdi, and S.B. Howell The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells Mol. Pharmacol. 64 2003 466 473
47. K. Katano, R. Safaei, G. Samimi, A. Holzer, M. Tomioka, M. Goodman, and S.B. Howell Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells Clin. Cancer Res. 10 2004 4578 4588
48. R.D. Kennedy, J.E. Quinn, P.B. Mullan, P.G. Johnston, and D.P. Harkin The role of BRCA1 in the cellular response to chemotherapy J. Natl. Cancer Inst. 96 2004 1659 1668
49. B. Krishan, M.G. Ormerod, S.B. Kaye, and A.L. Jackman Effective combinations of carboplatin with low doses of TRAIL, HGS-ETR1 and HGS-ETR2 in the TRAIL-sensitive HX62 human ovarian tumour cell line Eur. J. Cancer Suppl. 2 2004 19
50. K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, and C. Eng Frequent loss of PTEN expression in linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas Am. J. Pathol. 158 2001 2097 2106
51. C. Lee, K. Appleton, J.A. Plumb, S.B. Kaye, C. Cruickshank, P. Twelves, P.A. Vasey, I. Judson, R. Brown, and H. Mackay A phase I trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid tumours Proc. Am. Soc. Clin. Oncol. 23 2004 128
52. J.T. Lee Jr., L.S. Steelman, and J.A. McCubrey Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells Cancer Res. 64 2004 8397 8404
53. S. Lee, E.J. Choi, C. Jin, and D.H. Kim Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line Gynecol. Oncol. 97 2005 26 34
54. J. Li, Q. Feng, J.M. Kim, D. Schneiderman, P. Liston, M. Li, B. Vanderhyden, W. Faught, M.F. Fung, M. Senterman, R.G. Korneluk, and B.K. Tsang Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins Endocrinology 142 2001 370 380
55. A. Mansouri, L.D. Ridgway, A.L. Korapati, Q. Zhang, L. Tian, Y. Wang, Z.H. Siddik, G.B. Mills, and F.X. Claret Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells J. Biol. Chem. 278 2003 19245 19256
56. V. Materna, B. Liedert, J. Thomale, and H. Lage Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells Int. J. Cancer 115 2005 393 402
57. C.S. Mitsiades, and N. Mitsiades Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling Expert Rev. Anticancer Ther. 5 2005 487 499
58. R.B. Montgomery, J. Guzman, D.M. O'Rourke, and W.L. Stahl Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression J. Biol. Chem. 275 2000 17358 17363
59. P.J. Morin Drug resistance and the microenvironment: nature and nurture Drug Resist. Update 6 2003 169 172
60. S. Mozzetti, C. Ferlini, P. Concolino, F. Filippetti, G. Raspaglio, S. Prislei, D. Gallo, E. Martinelli, F.O. Ranelletti, G. Ferrandina, and G. Scambia Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients Clin. Cancer Res. 11 2005 298 305
61. T. Murata, M. Haisa, H. Uetsuka, T. Nobuhisa, T. Ookawa, Y. Tabuchi, Y. Shirakawa, T. Yamatsuji, J. Matsuoka, M. Nishiyama, N. Tanaka, and Y. Naomoto Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines Int. J. Mol. Med. 13 2004 865 868
62. K. Nakayama, A. Kanzaki, K. Terada, M. Mutoh, K. Ogawa, T. Sugiyama, S. Takenoshita, K. Itoh, N. Yaegashi, K. Miyazaki, N. Neamati, and Y. Takebayashi Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy Clin. Cancer Res. 10 2004 2804 2811
63. T. O'Hare, D.K. Walters, E.P. Stoffregen, T. Jia, P.W. Manley, J. Mestan, S.W. Cowan-Jacob, F.Y. Lee, M.C. Heinrich, M.W. Deininger, and B.J. Druker In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res. 65 2005 4500 4505
64. R.I. Pakunlu, T.J. Cook, and T. Minko Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and Bcl-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin Pharm. Res. 20 2003 351 359
65. B. Pan, K.S. Yao, B.P. Monia, N.M. Dean, R.A. McKay, T.C. Hamilton, and P.J. O'Dwyer Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype Biochem. Pharmacol. 63 2002 1699 1707
66. Y. Pengetnze, M. Steed, K.F. Roby, P.F. Terranova, and C.C. Taylor Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line Biochem. Biophys. Res. Commun. 309 2003 377 383
67. F. Petti, A. Thelemann, J. Kahler, S. McCormack, L. Castaldo, T. Hunt, L. Nuwaysir, L. Zeiske, H. Haack, L. Sullivan, A. Garton, and J.D. Haley Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930 Mol. Cancer Ther. 4 2005 1186 1197
68. P.A. Ple, T.P. Green, L.F. Hennequin, J. Curwen, M. Fennell, J. Allen, C. Lambert-Van Der Brempt, and G. Costello Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src J. Med. Chem. 47 2004 871 887
69. Y. Pommier, O. Sordet, S. Antony, R.L. Hayward, and K.W. Kohn Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks Oncogene 23 2004 2934 2949
70. M.R. Raspollini, G. Amunni, A. Villanucci, G. Baroni, A. Taddei, and G.L. Taddei c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study Ann. Oncol. 15 2004 594 597
71. D. Roberts, J. Schick, S. Conway, S. Biade, P.B. Laub, J.P. Stevenson, T.C. Hamilton, J. O'Dwyer P, and S.W. Johnson Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells Br. J. Cancer 92 2005 1149 1158
72. N. Sain, B. Krishnan, F. Yafai, M.G. Ormerod, S.B. Kaye, P. Workman, and A.L. Jackman Combination of the Hsp90 inhibitor, 17-AAG, with taxol in human ovarian tumour cell lines Proc. Am. Assoc. Cancer Res. 45 2004 458
73. A.K. Samanta, H.J. Huang, R.C. Bast Jr., and W.S. Liao Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB J. Biol. Chem. 279 2004 7576 7583
74. G. Samimi, G. Manorek, R. Castel, J.K. Breaux, T.C. Cheng, C.C. Berry, G. Los, and S.B. Howell cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance Cancer Chemother. Pharmacol. 55 2005 1 11
75. G. Samimi, R. Safaei, K. Katano, A.K. Holzer, M. Rochdi, M. Tomioka, M. Goodman, and S.B. Howell Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells Clin. Cancer Res. 10 2004 4661 4669
76. T. Schondorf, U.J. Gohring, G. Roth, I. Middel, M. Becker, N. Moser, M.M. Valter, and M. Hoopmann Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients Eur. J. Clin. Invest. 33 2003 256 260
77. M. Selvakumaran, D.A. Pisarcik, R. Bao, A.T. Yeung, and T.C. Hamilton Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res. 63 2003 1311 1316
78. Z.E. Selvanayagam, T.H. Cheung, N. Wei, R. Vittal, K.W. Lo, W. Yeo, T. Kita, R. Ravatn, T.K. Chung, Y.F. Wong, and K.V. Chin Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling Cancer Genet. Cytogenet. 154 2004 63 66
79. L. Shayesteh, Y. Lu, W.L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G.B. Mills, and J.W. Gray PIK3CA is implicated as an oncogene in ovarian cancer Nat Genet. 21 1999 99 102
80. C.A. Sherman-Baust, A.T. Weeraratna, L.B. Rangel, E.S. Pizer, K.R. Cho, D.R. Schwartz, T. Shock, and P.J. Morin Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells Cancer Cell 3 2003 377 386
81. V. Shridhar, K.C. Bible, J. Staub, R. Avula, Y.K. Lee, K. Kalli, H. Huang, L.C. Hartmann, S.H. Kaufmann, and D.I. Smith Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer Cancer Res. 61 2001 4258 4265
82. Y. Soh, S. Goto, M. Kitajima, S. Moriyama, K. Kotera, T. Nakayama, H. Nakajima, T. Kondo, and T. Ishimaru Nuclear localisation of glutathione S-transferase pi is an evaluation factor for drug resistance in gynaecological cancers Clin. Oncol. (R. Coll. Radiol.) 17 2005 264 270
83. D.B. Solit, Y. She, J. Lobo, M.G. Kris, H.I. Scher, N. Rosen, and F.M. Sirotnak Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel Clin. Cancer Res. 11 2005 1983 1989
84. N.L. Spector, W. Xia, H. Burris III, H. Hurwitz, E.C. Dees, A. Dowlati, and B. O'Neil Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies J. Clin. Oncol. 23 2005 2502 2512
85. F. Spinella, L. Rosano, V. Di Castro, M.R. Nicotra, P.G. Natali, and A. Bagnato Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells J. Biol. Chem. 278 2003 41294 41301
86. G. Strathdee, J.K. Vass, K.A. Oien, N. Siddiqui, J. Curto-Garcia, and R. Brown Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy Gynecol. Oncol. 97 2005 898 903
87. J.M. Summy, and G.E. Gallick Src family kinases in tumor progression and metastasis Cancer Metastasis Rev. 22 2003 337 358
88. M. Sun, G. Wang, J.E. Paciga, R.I. Feldman, Z.Q. Yuan, X.L. Ma, S.A. Shelley, R. Jove, P.N. Tsichlis, S.V. Nicosia, and J.Q. Cheng AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells Am J Pathol. 159 2001 431 437
89. M. Szyf DNA methylation and cancer therapy Drug Resist. Update 6 2003 341 353
90. I. Vasilevskaya, and P.J. O'Dwyer Role of Jun and Jun kinase in resistance of cancer cells to therapy Drug Resist. Update 6 2003 147 156
91. C.F. Verschraegen, H.O. Smith, F.C. Lee, C. Cathcart, and J.P. Norenberg Tlk-286 IDrugs 7 2004 771 781
92. F. Wang, Y. Zhu, Y. Huang, S. McAvoy, W.B. Johnson, T.H. Cheung, T.K. Chung, K.W. Lo, S.F. Yim, M.M. Yu, H.Y. Ngan, Y.F. Wong, and D.I. Smith Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis Oncogene 24 2005 3875 3885
93. A.E. Wakeling Inhibitors of growth factor signalling Endocr. Relat. Cancer 12 Suppl. 1 2005 S183 S187
94. R.P. Wernyj, and P.J. Morin Molecular mechanisms of platinum resistance: still searching for the Achilles' heel Drug Resist. Update 7 2004 227 232
95. J.R. Wiener, T.C. Windham, V.C. Estrella, N.U. Parikh, P.F. Thall, M.T. Deavers, R.C. Bast, G.B. Mills, and G.E. Gallick Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers Gynecol. Oncol. 88 2003 73 79
96. J. Williams, P.C. Lucas, K.A. Griffith, M. Choi, S. Fogoros, Y.Y. Hu, and J.R. Liu Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease Gynecol. Oncol. 96 2005 287 295
97. L.A. Wilson, H. Yamamoto, and G. Singh Role of the transcription factor Ets-1 in cisplatin resistance Mol. Cancer Ther. 3 2004 823 832
98. P. Workman Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 206 2004 149 157
99. X. Yang, H. Xing, Q. Gao, G. Chen, Y. Lu, S. Wang, and D. Ma Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells Gynecol. Oncol. 97 2005 413 421
100. X. Yang, F. Zheng, H. Xing, Q. Gao, W. Wei, Y. Lu, S. Wang, J. Zhou, W. Hu, and D. Ma Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer J. Cancer Res. Clin. Oncol. 130 2004 423 428
101. C.K. Youn, M.H. Kim, H.J. Cho, H.B. Kim, I.Y. Chang, M.H. Chung, and H.J. You Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents Cancer Res. 64 2004 4849 4857
102. L. Yu, and Z. Wang Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines J. Huazhong Univ. Sci. Technol. Med. Sci. 24 2004 151 153
103. Z.Q. Yuan, R.I. Feldman, G.E. Sussman, D. Coppola, S.V. Nicosia, and J.Q. Cheng AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance J. Biol. Chem. 278 2003 23432 23440
104. Z.Q. Yuan, M. Sun, R.I. Feldman, G. Wang, X. Ma, C. Jiang, D. Coppola, S.V. Nicosia, and J.Q. Cheng Frequent activation of Akt2 and induction of apoptosis by inhibition of phopsphoinositide-3-OH kinase/Akt pathway in human ovarian cancer Oncogene 19 2000 2324 2330
105. T. Zhang, M. Guan, H.Y. Jin, and Y. Lu Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells Gynecol. Oncol. 97 2005 501 507
106. C. Zhou, J.L. Smith, and J. Liu Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1 Oncogene 22 2003 2396 2404